Insiders Keep Buying InspireMD Shares Amid Stock Slide: Senior Executive Stuka Paul Adds 10,000 Shares, Confidence Signals Persist

Insider Buying Continues at InspireMD

The latest Form 4 reveals that senior executive Stuka Paul purchased 10 000 shares of InspireMD common stock on 13 May 2026 at a weighted average price of $1.16. With the purchase, his stake climbed to 642 871 shares, or roughly 1.14 % of the outstanding shares. The transaction comes amid a week of heightened activity—CEO Marvin Slosman added 21 000 shares on 12 May, and several other executives completed sizable buys. The market, however, has been on a downtrend: the stock closed at $1.14, down 8.7 % for the week and more than 53 % year‑to‑date. Despite the price decline, insiders continue to add shares, suggesting confidence in the company’s long‑term trajectory.

What Does the Buying Mean for Investors?

Insider purchases are generally interpreted as a signal that those with the most intimate view of a company believe its shares are undervalued or poised for upside. In this case, the cumulative insider buying since January has seen Paul acquire an additional ~119 000 shares (from 523 704 to 642 871), while other executives have added ~1.5 million shares in total. The volume is modest relative to the company’s market cap ($56 M), but the pattern of consistent, relatively high‑priced purchases (often near the trading price) indicates a willingness to invest in the company even as the stock has trended lower.

For investors, this can be a cue to monitor the company’s pipeline and financials more closely. InspireMD’s core product targets acute myocardial infarction (AMI) procedures, a niche but potentially high‑margin market. The company’s negative P/E of –1.69 and sharp quarterly declines raise concerns about short‑term profitability, yet the continued insider buying may point to a belief that the upcoming clinical milestones or regulatory approvals could reverse the downward trend. Those considering adding shares should weigh the risk of a still‑volatile stock against the potential upside of a successful product launch.

A Profile of Stuka Paul

Stuka Paul has been an active buyer of InspireMD stock over the past year. His transactions reveal a pattern of incremental purchases: from 132 076 shares in January 2026 to 65 626 shares in May, and two separate buys of 10 000 shares in mid‑May. He also held a significant block of 423 704 shares reported as a holding, indicating long‑term exposure. His trade history shows buying at prices ranging from $1.12 to $1.19, generally close to the market level, suggesting he is not chasing a bargain but rather investing a consistent amount in the company.

Unlike some insiders who sell off shares after a price spike, Paul’s activity is predominantly buying, with no recorded sales in the data provided. This consistent buying pattern is a positive signal for long‑term investors, hinting at confidence in the company’s direction. His holdings, while modest relative to the total shares outstanding, provide a tangible stake that aligns his interests with shareholders.

Bottom Line

Insider buying at InspireMD, especially from a senior executive like Stuka Paul, offers a subtle but meaningful confidence gauge. The company faces a challenging valuation backdrop, but the steady accumulation of shares by insiders suggests that the management believes in future upside. Investors should watch for forthcoming clinical milestones and any change in market sentiment—particularly given the recent social media buzz and the stock’s continued decline—to decide whether to follow the insiders’ lead.